Literature DB >> 22236923

Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.

C Pierre-Audigier1, C Surcouf, V Cadet-Daniel, A Namouchi, S Heng, A Murray, B Guillard, B Gicquel.   

Abstract

In a study performed in Cambodia, a higher number of tuberculosis (TB) strains with mutations in the pncA gene associated with pyrazinamide resistance (PZA-R) was found in fluoroquinolone-resistant (FQ-R) multidrug-resistant (MDR) strains (93%), compared with 47% in MDR and 3% in non-MDR strains. This emphasises the need for easy and rapid tests for identification of PZA-R for efficient treatment of MDR-TB.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236923     DOI: 10.5588/ijtld.11.0266

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  14 in total

1.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

2.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Authors:  Rokeya Tasneen; Kathy Williams; Opokua Amoabeng; Austin Minkowski; Khisimuzi E Mdluli; Anna M Upton; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

4.  High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Authors:  Jean-Philippe Lanoix; Rokeya Tasneen; Paul O'Brien; Jansy Sarathy; Hassan Safi; Michael Pinn; David Alland; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

5.  Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.

Authors:  Dange Li; Yi Hu; Jim Werngren; Mikael Mansjö; Xubin Zheng; Francis Drobniewski; Sven Hoffner; Biao Xu
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

6.  Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.

Authors:  Ekaterina V Kurbatova; Joseph S Cavanaugh; Tracy Dalton; Eleanor S Click; J Peter Cegielski
Journal:  Clin Infect Dis       Date:  2013-07-09       Impact factor: 9.079

Review 7.  'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility.

Authors:  Ying Zhang; Kwok Chiu Chang; Chi-Chiu Leung; Wing Wai Yew; Brigitte Gicquel; Dorothy Fallows; Gilla Kaplan; Richard E Chaisson; Wenhong Zhang
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

8.  In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.

Authors:  Pooja Gopal; Rokeya Tasneen; Michelle Yee; Jean-Philippe Lanoix; Jansy Sarathy; George Rasic; Liping Li; Véronique Dartois; Eric Nuermberger; Thomas Dick
Journal:  ACS Infect Dis       Date:  2017-03-16       Impact factor: 5.084

9.  A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.

Authors:  Mariam O Fofana; Sourya Shrestha; Gwenan M Knight; Ted Cohen; Richard G White; Frank Cobelens; David W Dowdy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

10.  Design, Synthesis and Antitubercular Evaluation of Novel Series of Pyrazinecarboxamide Metal Complexes.

Authors:  Mohsin Ali; Mansoor Ahmed; Saleem Hafiz; Mustafa Kamal; Majid Mumtaz; Seyed Abdulmajid Ayatollahi
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.